A retrospective study conducted at the University Health Network found that, in liver transplant recipients with diabetes, combination therapy reduced HbA1c and alanine aminotransferase levels more effectively than DPP-4 inhibitors. Additionally, two clinical trials in patients with Type 2 diabetes demonstrated that combination therapy significantly lowered HbA1c by 1.34% and 1.21%, compared to a 0.54% reduction with placebo, starting from a baseline of 8.0%. These findings suggest that combination therapy may be especially beneficial in the liver transplant population, where patients often experience weight gain and develop metabolic co-morbidities
These findings were supported by another study in which liraglutide improved diastolic function in diabetic patients [91, 92]
Men commonly experience metabolic changes, reduced muscle mass, and hormone fluctuations with age that can contribute to weight gain
This can help reduce feelings of fullness and nausea
Tirzepatide is a dual agonist that targets both GLP-1 and GIP receptors, which can lead to more significant improvements in blood sugar control and weight loss
Is injection or topical better for skin effects